Literature DB >> 9291328

Rates of hepatitis E virus infection and disease among adolescents and adults in Kathmandu, Nepal.

E T Clayson1, M P Shrestha, D W Vaughn, R Snitbhan, K B Shrestha, C F Longer, B L Innis.   

Abstract

To determine hepatitis E virus (HEV) infection and disease rates in the Kathmandu Valley of Nepal, serum was collected from 757 healthy Nepalese (ages 12-48 years) during March and September 1992 and September 1993. At each visit, reports of interval illness were obtained. Sera were examined for IgG to HEV, using a commercially available kit. Seroconversion was used as a marker for HEV infection, and an episode of hepatitis E was defined as a history of jaundice with seroconversion. Seroprevalence ranged from 16% to 31% and increased with age, whereas both infection and disease rates decreased with age. Infection and disease rates were as high as 99/1000 and 45/1000 person-years, respectively. These results highlight the importance of sporadic hepatitis E as a public health problem among adolescents and young adults in this region.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291328     DOI: 10.1086/517296

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Novel risk factors associated with hepatitis E virus infection in a large outbreak in northern Uganda: results from a case-control study and environmental analysis.

Authors:  Christopher M Howard; Thomas Handzel; Vincent R Hill; Scott P Grytdal; Curtis Blanton; Saleem Kamili; Jan Drobeniuc; Dale Hu; Eyasu Teshale
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

2.  Outbreak of Viral Hepatitis E in a Regimental Training Centre.

Authors:  A Banerjee; A K Sahni; A Nagendra; G S Saiprasad
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 3.  Epidemiology of Genotype 1 and 2 Hepatitis E Virus Infections.

Authors:  Kenrad E Nelson; Alain B Labrique; Brittany L Kmush
Journal:  Cold Spring Harb Perspect Med       Date:  2019-06-03       Impact factor: 6.915

4.  Epidemiology and risk factors of incident hepatitis E virus infections in rural Bangladesh.

Authors:  Alain B Labrique; K Zaman; Zahid Hossain; Parimalendu Saha; Mohammad Yunus; Anowar Hossain; John R Ticehurst; Kenrad E Nelson
Journal:  Am J Epidemiol       Date:  2010-08-26       Impact factor: 4.897

5.  Epidemiological Investigation of an Outbreak of Viral Hepatitis.

Authors:  Pmp Singh; S K Handa; A Banerjee
Journal:  Med J Armed Forces India       Date:  2011-07-21

6.  Identification of swine hepatitis E virus (HEV) and prevalence of anti-HEV antibodies in swine and human populations in Korea.

Authors:  In-Soo Choi; Hyuk-Joon Kwon; Na-Ri Shin; Han Sang Yoo
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

7.  HEV-Capsid Protein Interacts With Cytochrome P4502C8 and Retinol-Binding Protein 4.

Authors:  Quan Shen; Wen Zhang; Yanjun Kang; Yan Chen; Li Cui; Zhibiao Yang; Xiuguo Hua
Journal:  Hepat Mon       Date:  2011-11-30       Impact factor: 0.660

8.  An exploratory case control study of risk factors for hepatitis E in rural Bangladesh.

Authors:  Alain B Labrique; K Zaman; Zahid Hossain; Parimalendu Saha; Mohammad Yunus; Anowar Hossain; John Ticehurst; Brittany Kmush; Kenrad E Nelson
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240

9.  Cloning of full genome sequence of hepatitis E virus of Shanghai swine isolate using RACE method.

Authors:  Quan Shen; Wen Zhang; Xiangrong Cao; Jing Mou; Li Cui; Xiuguo Hua
Journal:  Virol J       Date:  2007-10-09       Impact factor: 4.099

10.  Travel-related hepatitis E: a two-decade GeoSentinel analysis.

Authors:  Laura Ambra P Nicolini; Rhett J Stoney; Andrea Della Vecchia; Martin Grobusch; Philippe Gautret; Kristina M Angelo; Perry J J van Genderen; Emmanuel Bottieau; Karin Leder; Hilmir Asgeirsson; Daniel T Leung; Bradley Connor; Prativa Pandey; Federica Toscanini; Federico Gobbi; Francesco Castelli; Matteo Bassetti; Davidson H Hamer
Journal:  J Travel Med       Date:  2020-11-09       Impact factor: 39.194

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.